ImmuPharma reports 'significant' progress since restructure

The AIM-traded firm said the ‘Lupuzor’ pharmacokinetic study was on track to deliver results in the first quarter of 2022, and to move into phase 3 after that.

It also said a new proprietary synthesis of ‘P140’, dubbed P140/Lupuzor, had been created, giving greater intellectual property protection and cost efficiencies.

P140-CIDP, meanwhile, was moving into a phase 2 and 3 adaptive registration clinical trial in 2022, with expected 'orphan drug' designation.

Commercial partnering discussions in that area were reported to be ongoing, while ImmuPharma said its relationship with professor Sylviane Muller and the French National Centre for Scientific Research (CNRS) had been strengthened to exploit P140 opportunities.

Finally, the company reported “excellent” results from the preclinical study of BioAMB, with further significant updates expected in the first half of 2022.

Commercial partnering discussions on that front were also ongoing.

“The evolution and transition of ImmuPharma over the last few months can probably be summed up as one of the most challenging and yet exciting periods in its history,” said chief executive officer Tim McCarthy.

“An enormous amount of collaborative teamwork has been involved to achieve the vastly improved position we have presented today.

“As a board, supported by our excellent preclinical team in Bordeaux and our collaboration partners, we are all unified in our belief that ImmuPharma is now positioned to be able to deliver on the key objectives and timetable outlined in this announcement and we are excited by this new phase in the evolution of ImmuPharma.”

At 1438 GMT, shares in ImmuPharma were up 2.13% at 6.95p.